Mainstreaming patients with ovarian, endometrial, and colorectal cancer in the context of genetic testing at cancer diagnosis involves pre-test counseling, consent, and return of results by the clinical cancer team. This process uses significant clinician time and resources. Alternative implementation strategies might be more cost-efficient and better utilize limited cancer health professional and genetics workforce resources, but their efficacy is less well understood. To determine if direct-to-patient genetic testing for ovarian, endometrial, and colorectal cancer has equivalent uptake of genetic testing compared with mainstreaming. Patients at ovarian, endometrial, or colorectal cancer diagnosis have equivalent uptake for genetic testing through direct-to-patient compared with mainstreaming. A multicenter randomized controlled trial evaluating a digitally enabled direct-to-patient (saliva-based, at home) genetic testing approach (intervention arm) compared with mainstreaming genetic testing (control arm). After study consent and randomization, patients in the direct-to-patient arm are offered access to an app-based decision aid, consent to genetic testing via the app, and access to a helpline for additional support and counseling if needed. Control arm participants are offered routine mainstreaming genetic testing in the clinic. We include a qualitative sub-study of 1:1 interviews to understand the attitudes, experiences, and impact on emotional well-being of patients undergoing genetic testing. Inclusion criteria include diagnosis of ovarian, endometrial, or colorectal cancer fulfilling the National Health Service clinical genetic testing criteria. Exclusion criteria include prior genetic testing for or a known familial pathogenic variant in ovarian, endometrial, or colorectal cancer susceptibility genes. Absolute difference in uptake of genetic testing between arms in the intention-to-treat population, with equivalence determined using a 10% margin based on a 2-sided 95% confidence interval. Target n = 626 to 832 patients. We will test equivalence if ≥626 patients are recruited in the intention-to-treat population. Recruitment by December 2026 and publication of results in 2028. ISRCTN:57402067 (July 26, 2023). (https://doi.org/10.1186/ISRCTN57402067).